Aprea Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.62) Per Share, HC Wainwright Forecasts (NASDAQ:APRE)

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Aprea Therapeutics in a report released on Monday, August 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.62) for the quarter, down from their prior estimate of ($0.56). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2024 earnings at ($0.57) EPS, FY2024 earnings at ($2.41) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at ($0.51) EPS.

Separately, Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday.

Aprea Therapeutics Stock Up 11.4 %

NASDAQ APRE opened at $3.80 on Thursday. The stock has a fifty day simple moving average of $3.88 and a 200 day simple moving average of $5.23. The company has a market capitalization of $20.63 million, a price-to-earnings ratio of -1.14 and a beta of 1.04. Aprea Therapeutics has a twelve month low of $3.20 and a twelve month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.05. The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.78% and a negative net margin of 1,317.82%.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned 0.20% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.